Literature DB >> 22991081

[Variability in the reporting of adverse reactions to the pandemic and seasonal influenza vaccine: seasons 2009-2010 and 2010-2011. Valencian community, Spain].

Ana María Alguacil Ramos1, José Antonio Lluch Rodrigo, Antonio Portero Alonso, Rosa Martín Ivorra, Eliseo Pastor Villalba.   

Abstract

BACKGROUND: The loss of confidence in the safety of vaccines derived from alarm conditions, as in the case of the flu pandemic may affect both vaccination coverage and the sensitivity to the reporting of suspected adverse reactions associated vaccines (SRAAV). The aim of the study is to describe the adverse effects reported to the vaccine against pandemic influenza in the 2009-2010 season and against seasonal influenza in 2009-2010 and 2010-2011 seasons, by type of vaccine, risk groups and by age group in the Valencian Community (CV).
METHODS: A retrospective descriptive study has been made of the individuals presenting suspected adverse reactions to the influenza vaccine reported through the Vaccine Information System during the seasons 2009-2010 and 2010-2011 in the Valencian Community. 95% confidence intervals were calculated.
RESULTS: During the period 2009-2010 the reporting rate of suspected reactions for seasonal influenza vaccine was 0.020 per thousand doses administered, for the pandemic vaccine 0.95. The reporting rate for seasonal influenza vaccine in the period 2010-2011 was 0.04 per thousand.
CONCLUSIONS: There was an increase in the number of reported suspected adverse reactions to the pandemic vaccines compared with the rest of influenza vaccines, during the seasons. The highest suspected adverse reaction reporting rate was for the group of health professionals partner for both vaccines against seasonal and pandemic influenza.

Mesh:

Substances:

Year:  2012        PMID: 22991081     DOI: 10.1590/S1135-57272012000300004

Source DB:  PubMed          Journal:  Rev Esp Salud Publica        ISSN: 1135-5727


  2 in total

1.  Passive enhanced safety surveillance for Vaxigrip and Intanza 15 µg in the United Kingdom and Finland during the northern hemisphere influenza season 2015/16.

Authors:  Hélène Bricout; Anne Laure Chabanon; Audrey Souverain; Christine Sadorge; Timo Vesikari; Timothy David Caroe
Journal:  Euro Surveill       Date:  2017-05-04

2.  Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.

Authors:  Anne Laure Chabanon; Hélène Bricout; Céline Ballandras; Audrey Souverain; Timothy David Caroe; Karina M Butler
Journal:  Hum Vaccin Immunother       Date:  2017-12-20       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.